Evidence map›Paper›PMID 30590449›Full record

ArticleCerebral cortex (New York, N.Y. : 1991)2019

Ceftriaxone Treatment Preserves Cortical Inhibitory Interneuron Function via Transient Salvage of GLT-1 in a Rat Traumatic Brain Injury Model.

Mustafa Q Hameed, Tsung-Hsun Hsieh, Leon Morales-Quezada, Henry H C Lee, Ugur Damar, Paul C MacMullin, Takao K Hensch, Alexander Rotenberg

Open access · greenAbstract read
In one paragraph

Article in Cerebral cortex (New York, N.Y. : 1991), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Synaptic Pathology in Traumatic Brain Injury and Therapeutic Insights.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome.Annals of clinical and translational neurology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mustafa Q HameedDepartment of Neurology, Division of Epilepsy and Clinical Neurophysiology, Neuromodulation Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Tsung-Hsun HsiehDepartment of Neurology, Division of Epilepsy and Clinical Neurophysiology, Neuromodulation Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Leon Morales-QuezadaSpaulding Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA.
Henry H C LeeDepartment of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Ugur DamarDepartment of Neurology, Division of Epilepsy and Clinical Neurophysiology, Neuromodulation Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Paul C MacMullinDepartment of Neurology, Division of Epilepsy and Clinical Neurophysiology, Neuromodulation Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Takao K HenschDepartment of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Alexander RotenbergDepartment of Neurology, Division of Epilepsy and Clinical Neurophysiology, Neuromodulation Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USBoston Children's Hospital · USChang Gung University · TW

Funding

Mapping progressive loss of intracortical inhibition by TMS and EEG in posttraumatic epileptogenesisR01NS088583 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI ROTENBERG, ALEXANDER · 2015 to 2019
$1.9M
NINDS NIH HHS R01 NS088583
6 · The paper itself

Abstract

Traumatic brain injury (TBI) results in a decrease in glutamate transporter-1 (GLT-1) expression, the major mechanism for glutamate removal from synapses. Coupled with an increase in glutamate release from dead and dying neurons, this causes an increase in extracellular glutamate. The ensuing glutamate excitotoxicity disproportionately damages vulnerable GABAergic parvalbumin-positive inhibitory interneurons, resulting in a progressively worsening cortical excitatory:inhibitory imbalance due to a loss of GABAergic inhibitory tone, as evidenced by chronic post-traumatic symptoms such as epilepsy, and supported by neuropathologic findings. This loss of intracortical inhibition can be measured and followed noninvasively using long-interval paired-pulse transcranial magnetic stimulation with mechanomyography (LI-ppTMS-MMG). Ceftriaxone, a β-lactam antibiotic, is a potent stimulator of the expression of rodent GLT-1 and would presumably decrease excitotoxic damage to GABAergic interneurons. It may thus be a viable antiepileptogenic intervention. Using a rat fluid percussion injury TBI model, we utilized LI-ppTMS-MMG, quantitative PCR, and immunohistochemistry to test whether ceftriaxone treatment preserves intracortical inhibition and cortical parvalbumin-positive inhibitory interneuron function after TBI in rat motor cortex. We show that neocortical GLT-1 gene and protein expression are significantly reduced 1 week after TBI, and this transient loss is mitigated by ceftriaxone. Importantly, whereas intracortical inhibition declines progressively after TBI, 1 week of post-TBI ceftriaxone treatment attenuates the loss of inhibition compared to saline-treated controls. This finding is accompanied by significantly higher parvalbumin gene and protein expression in ceftriaxone-treated injured rats. Our results highlight prospects for ceftriaxone as an intervention after TBI to prevent cortical inhibitory interneuron dysfunction, partly by preserving GLT-1 expression.

Indexed as

AnimalsAnti-Bacterial AgentsBrain Injuries, TraumaticCeftriaxoneDisease Models, AnimalExcitatory Amino Acid Transporter 2GABAergic NeuronsGene ExpressionInterneuronsMaleMotor CortexParvalbuminsRats, Sprague-DawleyAnti-Bacterial AgentsCeftriaxoneExcitatory Amino Acid Transporter 2ParvalbuminsSlc1a2 protein, ratceftriaxoneGLT-1intracortical inhibitionparvalbumintraumatic brain injury

Identifiers

PMID30590449
PMCPMC7150617
OpenAlexW2906165929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.